NASDAQ : APMD
Apnimed, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 16.4 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 682.74M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Details
| Name | Apnimed, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 81 |
| Founded | 2017 |
| Ipo Date | 2026-07-31 |
| Ceo | Kevin Lind |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US03770Y1073 |
| Cusip | 03770Y107 |
| Cik | 1745648 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Kevin Robert Lind | Chief Executive Officer and Director |
| Dr. Lawrence G. Miller M.D., M.P.H. | Founder and Vice Chair of the Board |
| Dennis Patrick Molnar M.B.A. | President and Chief Operating Officer |
| Dr. Luigi Taranto Montemurro M.D. | Co-Founder and Chief Scientific Officer |
| Michael B. Kelly | Chief Financial Officer |
| Leila Sylvain | Senior Manager of Administration |
| Steven W. Spector J.D. | Chief Legal Officer and Head of Corporate Affairs |
| Jennifer Patterson | Senior Vice President of Human Resources |
| Dr. John W. Cronin M.D. | Chief Medical Officer |
| Dr. Sean M. Johnston M.B.A., Ph.D. | Consulting Head of CMC |
Contact
| Address | 39 John F. Kennedy Street, 4th Floor, Cambridge, Massachusetts 02138, United States |
| Phone | 617 500 8880 |
| Website | https://apnimed.com |